Although no statistically significant differences were found, median PFS tended to be longer in patients with adenocarcinoma, EGFR wild type, stage IV, no liver metastasis, former smoker, ≥2 previous treatment lines, no previous VEGF or EGFR target therapies (Table 5 and Figures 4A–H). The gene discussed is EGFR; the disease is metastasis.